Veru Inc. (NASDAQ:VERU - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.59 and traded as high as $0.61. Veru shares last traded at $0.58, with a volume of 1,232,223 shares.
Veru Trading Down 2.8%
The firm's 50 day moving average is $0.58 and its two-hundred day moving average is $0.59. The firm has a market cap of $87.43 million, a P/E ratio of -2.49 and a beta of -0.75.
Veru (NASDAQ:VERU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Analysts predict that Veru Inc. will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Veru
Several institutional investors and hedge funds have recently modified their holdings of VERU. MPM Bioimpact LLC bought a new stake in Veru during the fourth quarter worth about $2,788,000. PVG Asset Management Corp lifted its holdings in shares of Veru by 64.4% in the fourth quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company's stock worth $681,000 after acquiring an additional 410,340 shares during the last quarter. Choreo LLC lifted its holdings in shares of Veru by 67.4% in the first quarter. Choreo LLC now owns 669,277 shares of the company's stock worth $328,000 after acquiring an additional 269,500 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Veru by 17.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,423,288 shares of the company's stock worth $698,000 after acquiring an additional 206,614 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Veru by 18.3% in the first quarter. Oppenheimer & Co. Inc. now owns 1,325,246 shares of the company's stock worth $650,000 after acquiring an additional 204,660 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Recommended Stories
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access